Leukemia
Leukemia
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
23
Clinical Trials
Leukemia
Phase III
Enrolling
nct/study# NCT05949684 / CA056-025
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / CHIP-ASCT
Impact of Clonal Hematopoiesis of Undetermined Potential (CHIP) Mutations on Engraftment Kinetics After Autologous Stem Cell Transplantation in Multiple Myeloma
Learn More
Leukemia
N/A
Enrolling
nct/study# N/A / CHIP-MYELOID
Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations and Risk of Subsequent Myeloid Malignancies in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant (ASCT)
Learn More
Leukemia
Phase I/II
Enrolling
nct/study# NCT04990102 / CPX351/VYXEOS
Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation
Learn More
Leukemia
Phase III
Enrolling
nct/study# NCT06423911 / HQP1351CG301
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Learn More
Leukemia
Phase I/II
Enrolling
nct/study# NCT04067336 / KO-MEN-001
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.